NASDAQ: AUPHAurinia Pharmaceuticals Inc Stock
$8.12+0.12 (+1.5%)
Updated May 12, 2025
AUPH Price
$8.12
Fair Value Price
N/A
Market Cap
$1.10B
52 Week Low
$5.08
52 Week High
$10.67
P/E
28x
P/B
3.13x
P/S
4.52x
PEG
0.48x
Dividend Yield
N/A
Revenue
$247.30M
Earnings
$39.85M
Gross Margin
88.2%
Operating Margin
18.77%
Profit Margin
16.1%
Debt to Equity
0.44
Operating Cash Flow
$64M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AUPH Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AUPH's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AUPH
Ranked#2 of 456
Ranked#2 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $66.58 | A | |
| $60.85 | A |
Be the first to know about important AUPH news, forecast changes, insider trades & much more!
AUPH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AUPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUPH ($8.12) is trading above its intrinsic value of $7.41, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AUPH is poor value based on its earnings relative to its share price (28x), compared to the US market average (24.73x)
P/E vs Market Valuation
AUPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AUPH due diligence checks available for Premium users.
Valuation
AUPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28x
Industry
-169.48x
Market
24.73x
AUPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AUPH is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
AUPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.13x
Industry
4.24x
AUPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUPH price to earnings growth (PEG)
For valuing profitable companies with growth potential
AUPH is good value based... subscribe to Premium to read more.
PEG Value Valuation
AUPH's financial health
Profit margin
Revenue
$62.5M
Net Income
$23.3M
Profit Margin
37.4%
AUPH's Earnings (EBIT) of $46.43M... subscribe to Premium to read more.
Interest Coverage Financials
AUPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$504.9M
Liabilities
$154.7M
Debt to equity
0.44
AUPH's short-term assets ($405.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUPH's short-term assets ($405.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AUPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.3M
Investing
$31.0M
Financing
-$49.3M
AUPH's operating cash flow ($64.29M)... subscribe to Premium to read more.
Debt Coverage Financials
AUPH vs Biotech Stocks
Aurinia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.